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Abstract
Objecti6es : It is suggested that during menopausal transition, women with vasomotor symptoms benefit from HRT,
(hormone replacement therapy) whereas, the use of HRT for other cognitive–vegetative symptoms is questionable.
Methods : The occurence of menopausal complaints and depressive symptoms was assessed cross-sectionally in 5896
Dutch Caucasian women (47–54 years) of a large community sample in the city of Eindhoven, The Netherlands.
Menopausal complaints were assessed using a 22 items self-rating scale (consisting of a vasomotor , uro-genital and
a cognitive–vegetative subscale). Depressive symptoms were assessed using the Edinburgh depression scale (EDS).
Differences in mean scores were analysed between groups using ANOVA. The independent relationship of depressive
symptoms to the intensity of menopausal complaints was assessed, by multiple linear regression analysis. Results :
Women using HRT showed the highest scores on all subscales. Oral contraceptive users had significantly lower scores
on the vasomotor subscale compared to HRT users and to non users. Depressive symptoms contributed the most, to
the explained variance on scores on the menopausal subscales. Conclusions : Women during menopause presenting
several complaints, other than vasomotor origin might be suffering from underlying depression which makes it
questionable to prescribe HRT for the latter symptoms. © 2000 Elsevier Science Ireland Ltd. All rights reserved.
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1. Introduction
According to a recent WHO report [1] depres-
sion has become a major health problem. The
prevalence rate is high, the burden of illness ex-
tensive and, as a consequence, the economic costs
are considerable [2]. A recent survey in the
Netherlands revealed a point prevalence of 8% in
the general population [3]. Despite the fact, that
treatment strategies have markedly improved, it is
estimated that only 20% of depressed patients
receive adequate therapy [1]. It is thought that the
non awareness of signs and symptoms of depres-
sion in the general population, could partly ex-
plain the underestimation of depression as a
major health problem. Moreover, in up to 50% of* Corresponding author.
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PII: S 0378 -5122 (99 )00093 -6
L.W. Maartens et al. / Maturitas 34 (2000) 113–118114
depressed patients who visit their general practi-
tioner, the symptoms are misdiagnosed [4] and
therefore accurate detection should result in more
appropriate therapy.
In general practice, it is well known that pa-
tients presenting various and often vague com-
plaints, may be suffering from underlying
depression. Also, during menopausal transition, it
is said that 50–70% of women experience all
kinds of somatic and emotional symptoms [5].
While vasomotor (flushing) and uro-genital (vagi-
nal dryness) symptoms are widely recognised as
being a direct consequence of the declining estro-
gen production during menopausal transition,
there is much debate concerning the specificity of
cognitive, vegetative and emotional symptoms in
the climacteric. Nevertheless, for the latter symp-
toms as well, a huge amount of estrogens are
prescribed (hormone replacement therapy, HRT)
to relieve the inconvenience in these women. It is
a matter of speculation whether women, who
present a whole range of vague complaints are in
fact suffering from underlying depression. If so, it
could be questioned whether the prescription of
hormone replacement therapy for these symptoms
is justified.
In a large community sample of women, rang-
ing in age from 47 to 54 years, we investigated the
extent to which perimenopausal complaints are
associated with depression.
2. Material and methods
2.1. Subjects
Between September 1994 and 1995 all women
(n=8503) born between 1941 and 1947 in the city
of Eindhoven, The Netherlands, were invited to
participate in a screening programme for os-
teoporosis: the Eindhoven perimenopausal os-
teoporosis study (EPOS) [6]. A total of 6648
women (78%) consented to participate. During
the screening, an accurate medical history was
obtained. Subsequently, the women were asked to
complete several questionnaires at home and to
return these within 1 week after screening.
Because of possible language problems, only
Dutch Caucasian women (5896, 89%) were in-
cluded in the analysis. Ninety-two percent (5424)
returned the questionnaires, 76% of which (4146)
were correctly completed. In order to avoid any
possible bias from gynaecological operations, all
women who had undergone a hysterectomy and/
or a uni- or bilateral ovariectomy (n=1117) were
excluded from the analysis. Therefore, the data
analysis covers the remaining 3029 women (Table
1). No differences in the characteristics were
found between the original sample and the sample
from this study (mean age, educational level, em-
ployment, marital status, having had children,
mean BMI and menopausal status.). Estrogen use,
was somewhat higher in the original sample (14 vs
10%), which was largely explained by the presence
of ovariectomised women. Of the 3029 women,
377 (12%) still used hormonal oral contraception
(OC), 320 (10%) were on HRT, while 2332
women were not using any estrogen therapy.
The study was approved by the medical ethics
committee of the St Joseph’s Hospital in Veld-
hoven, The Netherlands.
2.2. Assessment of menopausal complaints
The occurrence of menopausal complaints was
assessed using the 24-item self-rating scale which
has been validated earlier [7]. Moreover, we added
three items: vaginal dryness, pain during inter-
course and waking up at night, which, according
to the literature, are also specific for the transition
to menopause [8,9]. The psychometric properties
of this 27-item self-rating scale were analysed in
the women not using any hormonal substitution
(n=2332). Principal compound factor analysis
showed that 22 items loaded significantly and
covered three subscales: a vasomotor subscale
(three items: flushing, day sweating, night sweat-
ing, range 0–9), an uro-genital subscale (four
items: vaginal dryness, pain with cohabitation,
vaginal itching and burning on micturation, range
0–12) and a cognitive–vegetative subscale (15
items: irritability, lack of energy, depressed mood,
lack of self confidence, agitation, forgetfulness,
tiredness on waking, headache, tiredness, dizzi-
ness, muscle pain, shortness of breath, restless
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legs, palpitations and insomnia, range 0–45) with
a Cronbach’s alpha of 0.90, 0.88, and 0.65, re-
spectively, reflecting adequate internal
consistency.
2.3. Assessment of depressi6e symptoms
Depressive symptoms were assessed using the
Edinburgh depression scale (EDS), which is a ten-
item self-rating scale originally designed for use in
postpartum women and recently validated in mid-
dle aged non childbearing women [10,11,15].
Scores varied between 0 and 30 (with higher
scores indicating more depressive symptomatol-
ogy) with a commonly used cut-off score of 12.
2.4. Statistical analysis
Statistical analysis was performed using the
statistical products and service solutions (SPSS).
Correlations between the various scales were
analysed by means of Pearson’s correlation coeffi-
cient (using two-tailed P-values). Differences in
mean scores on several scales were analysed be-
tween groups, using ANOVA. In order to detect
differences between these groups, a post hoc anal-
Table 1
Characteristics of the samples of Dutch Caucasian women in the EPOS study
Total sample Study sample
n=5896 (%) n=3029 (%)
50.0Mean age (year) (SD) (2.1) 49.8 (2.1)
Educational le6el
(12.8)668 (10.7)Primary school 324
Lower professional education 1821 (35.0) 1009 (33.3)
Secondary modern education (27.4)830(26.5)1379
188(5.9) (6.2)306Secondary professional education
(7.3)High modern education 245380 (8.1)
562 (10.8)High professional education 382 (12.6)
Academic 83 (1.6) 51 (1.7)
Employment (35.9)1087(32.1)1892
Marital status
With partner 4492 (76.2) 2393 (79.0)
(21.0)636(23.8)1404Single
Children
772 (13.1) 424 (14.0)No
907 (15.4)1 454 (14.9)
(71.5)4217]2 (71.1)2151
(4.5)Mean body mass index 25.4 25.1 (4.3)
788 (26.0)1415Current smoking (23.9)
4717 (80.0) 2514Regular alcohol intake (82.9)
Gyneacological status
(18.9)1117 –Hysterectomy and/or ovariectomy –
826 (14.0)Use of HRT 320 (10.6)
(9.0)Use of OAC 377531 (12.4)
(76.9)2332(75.6)No use of estrogen/progesterone 4463
982 (22.2) 513 (21.9)Premenopause
2276 (51.0)Perimenopause 1189(50.9)
(27.1)630(26.9)1205Postmenopause
L.W. Maartens et al. / Maturitas 34 (2000) 113–118116
Table 2
Differences in mean scores on the menopausal self rating scale, its subscales and the EDS score, between women with hormone
replacement therapy (HRT), oral contraceptives (OC) and non users (ANOVA)
OC users (n=377) Non users (n=2332) FHRT users (n=320) P
Vasomotor scale
(2.81) 1.59 (2.21)* 2.332.43 (2.69)Mean score (SD) 11.02 B0.001
Urogenital scale
(2.21) 1.28 (1.97) 1.291.66 (2.01)Mean score (SD) 3.08 B0.04
Cogniti6e/Vegetati6e scale
(9.47)* 11.82 (9.13) 11.9315.30 (9.28)Mean score (SD) 16.92 B0.001
EDS score
(6.13)* 6.58 (5.8) 6.388.04 (5.72)Mean score (SD) 10.73 B0.001
ysis was performed using the Scheffe procedure.
The independent relationship of depressive symp-
toms to the intensity of menopausal complaints
was assessed by multiple linear regression analy-
sis, taking into account several other independent
variables known from the literature to interfere
with climacteric signs, such as age, body mass
index, parity, educational level, employment, mar-
ital status, and current smoking habits.
3. Results
The EDS was highly correlated to the cogni-
tive–vegetative subscale and to a lesser degree to
the vasomotor and urogenital subscales (0.72,
0.41 and 0.37, respectively, two tailed PB0.001).
Table 2 (ANOVA) shows the differences in
mean scores on the menopausal self-rating sub-
scales and the EDS between women using HRT
or OC and non users. Women using HRT showed
the highest scores on all subscales. In a post hoc
analysis following the Scheffe procedure, on the
EDS and the cognitive–vegetative subscale, the
scores of the HRT users were significantly higher
than the scores of those using OC and of those of
non users. Moreover, OC users had significantly
lower scores on the vasomotor subscale compared
to HRT users and to non users. On the uro-geni-
tal subscale, HRT users had higher (although not
significantly) scores than the OC users and the
non users. The scores on the menopausal sub-
scales in the different groups (HRT, OC and non
users) were used as dependent variables for multi-
ple linear regression analysis, with the EDS scores
and several other variables being used as indepen-
dent variables (Table 3). In all groups, the EDS
scores contributed the most to the explained vari-
ance on the subscales. Of the non users, only
postmenopausal status (no period for at least 12
months) proved to be a more important determi-
nant of the variance of the scores on the vasomo-
tor subscale.
4. Discussion
Although, during menopausal transition,
women experience many somatic and emotional
symptoms, no direct correlation with the declining
estrogen production has ever been demonstrated
[12]. Moreover, the overall lack of clear positive
findings regarding any positive effect of HRT on
emotional symptoms is disappointing [13,14]. It is
known from clinical practice that women who
present all kinds of complaints, may well be suf-
fering from underlying depression. This paper ex-
amined the association between depression and
the presentation of climacteric complaints.
Comparing cognitive and vegetative scores on a
menopausal self-rating scale to scores on a depres-
sion self-rating scale (EDS) revealed a very high
correlation (0.72), suggesting that symptoms
which are commonly regarded as being ‘typically’
related to menopausal transition, actually reflect
depressive symptomatology. If there is any rela-
tionship between declining estrogen production

















Multiple linear regression analysis with scores of climacteric complaints on the self rating questionnaire sub scales as dependent variable
Aa (n=320) Bb (n=377) Cc (n=2332)Sample
Total scale Vasomotor Cognitive veg-Urogenital Uro-genitalCognitive veg- VasomotorTotal scale Vasomotor Total scaleUro genital Cognitive veg-
scalescale scaleetative scale etative scale scalescale Scale etative Scale
0.530.47Adjusted R 0.11 0.04 0.53 0.45 0.09 0.02 0.49 0.50 0.18 0.10
square
Beta Beta Beta
0.04 0.03 0.07 0.02 0.05 0.06 0.07Age 0.03 0.01 0.03 −0.00 0.01
0.07* 0.16* 0.03 0.06 0.09* 0.15*BMI 0.11 0.04 0.06* 0.09* 0.00 0.05*
Parity −0.05 −0.05 −0.08 −0.03 −0.05 −0.07 −0.08 −0.02 −0.03 −0.03 −0.04 −0.02
0.67* 0.25* 0.22* 0.72* 0.66* 0.30*EDS 0.14* 0.69* 0.65* 0.21* 0.26* 0.70*
0.03−0.04 −0.11* −0.01 −0.01 0.03Education 0.01 0.01 0.03 0.00 −0.07* −0.02
level
−0.07 0.02 0.02 −0.08* −0.08Employment 0.05 −0.06 −0.01* −0.07* −0.04*−0.00 −0.07*
−0.07Marital status −0.09 −0.11 −0.04 0.00 −0.03 0.00 0.01 −0.02 −0.04 −0.01* 0.00
0.07 0.04 0.02 0.08 0.06 0.07Smoking −0.04 0.06 0.06* 0.08* −0.05* 0.06*
– –Menopause – – – – – – 0.15* 0.28* 0.17* 0.07*
a Women receiving HRT.
b Women receiving OAC.
c Women not receiving any estrogen.
* PB0.05.
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pothesised that women taking HRT should have
lower scores on the EDS than non users. This was
not the case in our study (Table 2): the highest
scores on the EDS were recorded in HRT users.
Subsequent multiple linear regression analysis
(Table 3) with scores on the menopausal subscales
as the dependent variable, showed that depressive
symptomatology contributed most strongly to the
explained variance within all groups. Moreover, in
the non users, postmenopausal status usually con-
tributed to high scores on the vasomotor subscale
and, to a minor degree, on the uro-genital subscale,
but almost never to high scores on the cognitive–
vegetative subscale. This suggests that declining
estrogen production is indeed associated with vaso-
motor symptoms, whereas it has hardly any effect
on cognitive and vegetative symptoms.
As far as we know, this is the first study to
investigate the correlation between depressive
symptomatology and menopausal complaints (tak-
ing into account the effect of hormone substitu-
tion) in a cohort of women representatives, of the
female population aged between 47 and 54 years.
What is the clinical relevance of these findings?
Firstly, it might be suggested that, during
menopausal transition, women with vasomotor
symptoms, benefit from HRT, whereas the use of
HRT for other ‘emotional’ symptoms is question-
able. Secondly, and even more importantly, the
general practitioner who is consulted by a woman
presenting several complaints of other than of
vasomotor origin, should realise that she might be
suffering from underlying depression. This would
hopefully lead to a more accurate diagnosis of
depression and, as a consequence, to more appro-
priate treatment: counselling and/or the use of
anti-depressants instead of a prescription for HRT.
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